AstraZeneca Targets Hetero Over Nexium ANDA
The plaintiff alleges that Hetero's submission of an abbreviated new drug application seeking the U.S. Food and Drug Administration's approval of its generic Nexium capsules infringes on a trio of AstraZeneca's patents.
“Hetero is aware that its [ANDA], if approved, will be used in contravention of plaintiffs’ rights" under the patents, the complaint says.
The patents-in-suit are U.S. Patent Numbers 5,714,504,...
To view the full article, register now.